DocMorris AG

ROSE

CH0042615283

Drug Retailers

Real-time Estimate Cboe Europe Other stock markets 13:29:18 17/07/2024 BST			5-day change	1st Jan Change
45.44 ^CHF	-3.69%		-21.07%	-37.87%

12:28pm	DOCMORRIS : Warburg Research reaffirms its Buy rating	ZD
07-12	DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	ZD

DOCMORRIS : Warburg Research reaffirms its Buy rating

July 17, 2024 at 11:28 am

Warburg Research analyst Michael Heider maintains his Buy rating on the stock. The target price is lowered from CHF 100 to CHF 60.

Latest news about DocMorris AG

DOCMORRIS : Warburg Research reaffirms its Buy rating	11:28am	ZD
DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	07-12	ZD
DOCMORRIS : Deutsche Bank reiterates its Buy rating	07-12	ZD
DOCMORRIS : Warburg Research maintains a Buy rating	07-11	ZD
DOCMORRIS : Sell rating from UBS	07-11	ZD
DocMorris' H1 Revenue Grows; FY24 Outlook Affirmed	07-11	MT
Redcare continues to recover - business with e-prescription picks up	07-04	DP
DOCMORRIS : Jefferies keeps its Buy rating	07-02	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	06-19	ZD
DOCMORRIS : Jefferies gives a Buy rating	06-05	ZD
DOCMORRIS : Receives a Sell rating from UBS	06-04	ZD
Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	05-27	DP
DOCMORRIS : Warburg Research reiterates its Buy rating	05-27	ZD
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	05-23
DOCMORRIS : Gets a Buy rating from Baader Bank	05-22	ZD
UBS sends Redcare and DocMorris share prices plummeting	05-21	DP
DOCMORRIS : Gets a Sell rating from UBS	05-21	ZD
DOCMORRIS : Sell rating from UBS	05-16	ZD
DocMorris Names Successor to Outgoing CFO	05-08	MT
DocMorris Launches Tender Offer for Convertible Bonds Due 2025	05-06	MT
ROUNUP: E-prescription advertising squeezes profit margin of online pharmacy Redcare	04-25	DP
DOCMORRIS : Deutsche Bank remains its Buy rating	04-23	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	04-19	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	04-18
DOCMORRIS : Gets a Buy rating from Warburg Research	04-18	ZD

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.18 CHF

Average target price

91.83 CHF

Spread / Average Target

+94.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-37.33%	679M
WALGREENS BOOTS ALLIANCE, INC.	-55.07%	10.13B
JD HEALTH INTERNATIONAL INC.	-44.50%	8.54B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-19.34%	6.49B
MATSUKIYOCOCOKARA & CO.	-3.00%	6.29B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+92.00%	5.25B
NAHDI MEDICAL COMPANY	-2.63%	4.61B
CLICKS GROUP LIMITED	+6.16%	4.55B
YIFENG PHARMACY CHAIN CO., LTD.	-33.29%	3.72B
REDCARE PHARMACY NV	+7.07%	3.1B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

DOCMORRIS : Warburg Research reaffirms its Buy rating

Latest news about DocMorris AG

Chart DocMorris AG

Company Profile

Income Statement Evolution

Ratings for DocMorris AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers